Gene Therapy Targeting Pkp2 Deficiency Attenuates Cardiac Fibrosis: Insights From Single-Cell Transcriptomics in Pkp2-Knockout Rats

Abstract

Heart failure (HF), characterized by maladaptive cardiac fibrosis and progressive functional deterioration, remains a therapeutic challenge. In this study, we established a cardiac organoid HF model derived from human-induced pluripotent stem cells (hiPSCs) and observed a significant downregulation of the desmosomal protein plakophilin-2 (PKP2) in this model. Reduced PKP2 expression was detected in both HF rat and mouse. Subsequent in vivo studies on Pkp2-knockout (Pkp2-KO) rats demonstrated that adeno-associated virus serotype 9 (AAV9)-mediated restoration of PKP2 not only restored cardiac PKP2 expression but also attenuated the progression of fibrosis. Administration of AAV9-PKP2 could also inhibit myocardial fibrosis and slow down disease progression in HF mouse. Single-cell RNA sequencing analysis in rats revealed enriched pathological profibrotic cardiac fibroblasts (CFs) in PKP2-deficient myocardium. Mechanistically, AAV9-PKP2 administration induced the phenotypic conversion of activated CFs into quiescent antifibrotic states. Integrated bioinformatics identified that protein tyrosine phosphatase receptor type C (Ptprc) was a pivotal regulator orchestrating this cellular reprogramming. Our findings thus unveil PKP2 as a master regulator of fibroblast activation and propose AAV9-PKP2 gene therapy as a promising novel therapeutic strategy targeting pathological fibrosis in HF.

Keywords

heart failure / myocardial fibrosis / PKP2 / Ptprc

References

[1] E. M. Boorsma, J. M. Ter Maaten, and K. Damman, “Congestion in Heart Failure: A Contemporary Look at Physiology, Diagnosis and Treatment,” Nature Reviews Cardiology 17, no. 10 (2020): 641-655.

[2] B. A. Borlaug, “Evaluation and Management of Heart Failure With Preserved Ejection Fraction,” Nature Reviews Cardiology 17, no. 9 (2020): 559-573.

[3] E. Tanai and S. Frantz, “Pathophysiology of Heart Failure,” Comprehensive Physiology 6, no. 1 (2015): 187-214.

[4] J. J. McMurray and M. A. Pfeffer, “Heart Failure,” Lancet 365, no. 9474 (2005): 1877-1889.

[5] A. González, E. B. Schelbert, J. Díez, and J. Butler, “Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives,” Journal of the American College of Cardiology 71, no. 15 (2018): 1696-1706.

[6] M. Delmar and W. J. McKenna, “The Cardiac Desmosome and Arrhythmogenic Cardiomyopathies: From Gene to Disease,” Circulation Research 107, no. 6 (2010): 700-714.

[7] E. Delva, D. K. Tucker, and A. P. Kowalczyk, “The Desmosome,” Cold Spring Harbor Perspectives in Biology 1, no. 2 (2009): a002543.

[8] A. Mathavan, U. Krekora, M. Belaunzaran Dominguez, and A. Mathavan, “Heterozygous Desmoplakin (DSP) Variants Presenting With Early Onset Cardiomyopathy and Refractory Ventricular Tachycardia,” BMJ Case Reports 17, no. 2 (2024): e259308.

[9] N. A. Najor, “Desmosomes in Human Disease,” Annual Review of Pathology 13 (2018): 51-70.

[10] M. Pérez-Hernández, C. J. M. van Opbergen, N. Bagwan, et al., “Loss of Nuclear Envelope Integrity and Increased Oxidant Production Cause DNA Damage in Adult Hearts Deficient in PKP2: A Molecular Substrate of ARVC,” Circulation 146, no. 11 (2022): 851-867.

[11] S. Vencato, C. Romanato, A. Rampazzo, and M. Calore, “Animal Models and Molecular Pathogenesis of Arrhythmogenic Cardiomyopathy Associated With Pathogenic Variants in Intercalated Disc Genes,” International Journal of Molecular Sciences 25, no. 11 (2024): 6208.

[12] S. Ravassa, B. López, T. A. Treibel, et al., “Cardiac Fibrosis in Heart Failure: Focus on Non-Invasive Diagnosis and Emerging Therapeutic Strategies,” Molecular Aspects of Medicine 93 (2023): 101194.

[13] V. Novelli, K. Malkani, and M. Cerrone, “Pleiotropic Phenotypes Associated with PKP2 Variants,” Frontiers in Cardiovascular Medicine 5 (2018): 184.

[14] B. Murray and C. A. James, “Genotype-Phenotype Correlates in Arrhythmogenic Cardiomyopathies,” Current Cardiology Reports 24, no. 11 (2022): 1557-1565.

[15] S. L. Kim, M. A. Trembley, K. Y. Lee, et al., “Spatiotemporal Cell Junction Assembly in Human iPSC-CM Models of Arrhythmogenic Cardiomyopathy,” Stem Cell Reports 18, no. 9 (2023): 1811-1826.

[16] N. Niell, M. J. Larriba, G. Ferrer-Mayorga, et al., “The human PKP2/Plakophilin-2 Gene Is Induced by Wnt/β-catenin in Normal and Colon Cancer-Associated Fibroblasts,” International Journal of Cancer 142, no. 4 (2018): 792-804.

[17] K. Phadke, S. D'Anna, E. Torres Vega, et al., “Atrial Cardiomyopathy Resulting From Loss of Plakophilin-2 Expression: Response to Adrenergic Stimulation and Implications for the Exercise Response,” The Journal of Physiology (2024).

[18] A. D. Dubash, C. Y. Kam, B. A. Aguado, et al., “Plakophilin-2 Loss Promotes TGF-β1/p38 MAPK-Dependent Fibrotic Gene Expression in Cardiomyocytes,” Journal of Cell Biology 212, no. 4 (2016): 425-438.

[19] E. Kyriakopoulou, D. Versteeg, H. de Ruiter, et al., “Therapeutic Efficacy of AAV-Mediated Restoration of PKP2 in Arrhythmogenic Cardiomyopathy,” Nature Cardiovascular Research 2, no. 12 (2023): 1262-1276.

[20] I. Wu, A. Zeng, A. Greer-Short, et al., “AAV9:PKP2 Improves Heart Function and Survival in a Pkp2-Deficient Mouse Model of Arrhythmogenic Right Ventricular Cardiomyopathy,” Communications Medicine (London) 4, no. 1 (2024): 38.

[21] Y. Yan, T. Zhang, X. He, et al., “A Cardiac Fibroblast-Enriched Micropeptide Regulates Inflammation in Ischemia/Reperfusion Injury,” JCI Insight 10, no. 9 (2025): e187848.

[22] Z. Gao, “New Insights Into Smad3 in Cardiac Fibrosis,” Gene 952 (2025): 149418.

[23] E. A. Clark and N. V. Giltiay, “CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity,” Frontiers in Immunology 9 (2018): 2235.

[24] A. Azaouagh, S. Churzidse, T. Konorza, and R. Erbel, “Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: A Review and Update,” Clinical Research in Cardiology 100, no. 5 (2011): 383-394.

[25] A. Svensson, P. G. Platonov, K. H. Haugaa, et al., “Genetic Variant Score and Arrhythmogenic Right Ventricular Cardiomyopathy Phenotype in Plakophilin-2 Mutation Carriers,” Cardiology 146, no. 6 (2021): 763-771.

[26] A. K. Vimalanathan, E. Ehler, and K. Gehmlich, “Genetics of and Pathogenic Mechanisms in Arrhythmogenic Right Ventricular Cardiomyopathy,” Biophysical Reviews 10, no. 4 (2018): 973-982.

[27] Y. Hu, H. Jia, H. Cui, and J. Song, “Application of Spatial Omics in the Cardiovascular System,” Research (Wash D C) 8 (2025): 0628.

[28] E. Z. Tchilian and P. C. Beverley, “Altered CD45 Expression and Disease,” Trends in Immunology 27, no. 3 (2006): 146-153.

[29] M. L. Hermiston, Z. Xu, and A. Weiss, “CD45: A Critical Regulator of Signaling Thresholds in Immune Cells,” Annual Review of Immunology 21 (2003): 107-137.

[30] Y. M. Bai, S. Liang, and B. Zhou, “Revealing Immune Infiltrate Characteristics and Potential Immune-Related Genes in Hepatic Fibrosis: Based on Bioinformatics, Transcriptomics and Q-PCR Experiments,” Frontiers in Immunology 14 (2023): 1133543.

[31] Z. Fu, X. Geng, C. Liu, et al., “Identification of Common and Specific Fibrosis-Related Genes in Three Common Chronic Kidney Diseases,” Renal Failure 46, no. 1 (2024): 2295431.

[32] A. Serrano-Pozo, S. Das, and B. T. Hyman, “APOE and Alzheimer's Disease: Advances in Genetics, Pathophysiology, and Therapeutic Approaches,” Lancet Neurology 20, no. 1 (2021): 68-80.

[33] K. L. Rasmussen, “Plasma Levels of Apolipoprotein E, APOE Genotype and Risk of Dementia and Ischemic Heart Disease: A Review,” Atherosclerosis 255 (2016): 145-155.

[34] R. W. Mahley, “Apolipoprotein E: From Cardiovascular Disease to Neurodegenerative Disorders,” Journal of Molecular Medicine (Berlin) 94, no. 7 (2016): 739-746.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.